Pazopanib versus sunitinib in renal cancer.
作者信息
Ramaekers Ryan, Tharnish Mark, Copur M Sitki
出版信息
N Engl J Med. 2013 Nov 14;369(20):1968-9. doi: 10.1056/NEJMc1311795.
PMID:24224636
Abstract
摘要
相似文献
1
Pazopanib versus sunitinib in renal cancer.
N Engl J Med. 2013 Nov 14;369(20):1968-9. doi: 10.1056/NEJMc1311795.
2
Pazopanib versus sunitinib in renal cancer.
N Engl J Med. 2013 Nov 14;369(20):1970. doi: 10.1056/NEJMc1311795.
3
Pazopanib versus sunitinib in renal cancer.
N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795.
4
Pazopanib versus sunitinib in renal cancer.
N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795.
5
Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Eur Urol. 2014 May;65(5):1014-5. doi: 10.1016/j.eururo.2013.12.042.
6
Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Eur Urol. 2014 Mar;65(3):667-8. doi: 10.1016/j.eururo.2013.11.023.
7
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
N Engl J Med. 2014 May 1;370(18):1769-70. doi: 10.1056/NEJMc1400731.
8
Pazopanib outscores sunitinib on tolerability.
Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.
9
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
10
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Oncotarget. 2016 Jun 21;7(25):37599-37607. doi: 10.18632/oncotarget.9229.
Zotero 插件